First clinical data of a natural immunomodulator in colorectal cancer

Ferenc Jakab, Á Mayer, A. Hoffmann, M. Hidvégi

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background/Aims: MSC (trade-name AVEMAR®) is a per os applicable complex of multiple, biologically active molecules obtained from fermented wheat-germ extract. Preclinical studies suggest potent anti-metastatic activity and it has a favorable toxicity profile. It has been aimed in a pilot-scale, phase II clinical study to document whether or not MSC as a support to surgery or plus chemotherapy adds any therapeutic benefit compared to the same combination without MSC in colorectal cancer. Methodology: From 1998 to June 1999, 18 control patients and 12 consecutive colorectal cancer patients respectively, were enrolled into this study. All patients underwent curative surgery. The control group (18 patients) received no other therapy or adjuvant chemotherapy alone. The MSC group (12 patients) received MSC alone or plus adjuvant chemotherapy. Until now, the median follow-up has been 9 months. Results: Interim data of the study document that in the MSC group no new metastases, neither hepatic nor other, have occurred, so far. On the contrary, several new metastases have developed in the control group. Conclusions: Orally administered MSC is a potent candidate to be regarded as a supportive therapy to surgery or plus chemotherapy for colorectal cancer patients.

Original languageEnglish
Pages (from-to)393-395
Number of pages3
JournalHepato-Gastroenterology
Volume47
Issue number32
Publication statusPublished - May 3 2000

    Fingerprint

Keywords

  • Avemar
  • Colorectal cancer
  • Combination therapy
  • Fermented wheat-germ extract
  • Metastasis
  • Phase II clinical trial
  • Pilot study
  • Supportive therapy

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this